CEO David DeStefano highlighted Vertex's strong start to 2025, reporting $177.1 million in revenue, a 12.9% year-over-year increase, supported by 14.4% growth in subscription revenue and 29.6% growth ...

Vertex Pharmaceuticals (VRTX) is back in focus after Wolfe Research upgraded the stock to Outperform, citing increased confidence in its investigational IgA nephropathy therapy and plans to use a ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 ...

Vertex Pharmaceuticals stock declined almost 13% in six months due to poor test results for a new drug. When it comes to the drug and biotech sector, a major pipeline setback can hit the stock hard.

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of ...